Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jun;129(5-6):723-736.
doi: 10.1007/s00702-022-02465-w. Epub 2022 Feb 2.

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease

Wolfgang H Jost  1
Affiliations
Review

A critical appraisal of MAO-B inhibitors in the treatment of Parkinson's disease

Wolfgang H Jost. J Neural Transm (Vienna). 2022 Jun.

Abstract

Since the 1980s, the MAO-B inhibitors have gained considerable status in the therapy of the Parkinson's disease. In addition to the symptomatic effect in mono- and combination therapies, a neuroprotective effect has repeatedly been a matter of some discussion, which has unfortunately led to a good many misunderstandings. Due to potential interactions, selegiline has declined in significance in the field. For the MAO-B inhibitor safinamide, recently introduced to the market, an additional inhibition of pathological release of glutamate has been postulated. At present, rasagiline and selegiline are being administered in early therapy as well as in combination with levodopa. Safinamide has been approved only for combination therapy with levodopa when motor fluctuations have occurred. MAO-B inhibitors are a significant therapeutic option for Parkinson's disease, an option which is too often not appreciated properly.

Keywords: MAO-B inhibitors; Parkinson’s disease; Rasagiline; Safinamide; Selegiline.

PubMed Disclaimer

Conflict of interest statement

W. Jost is or was a consultant and/or speaker for the following companies: Abbvie, Bial, Desitin, Kyowa Kirin, Stada, UCB, Zambon.

Figures

Fig. 1
Fig. 1
Metabolism of selegiline and rasagiline (after Chen et al. 2007)
See this image and copyright information in PMC

References

    1. Abbruzzese G, Kulisevsky J, Bergmans B, Gomez-Esteban JC, Kägi G, Raw J, Stefani A, Warnecke T, Jost WH, SYNAPSES Study Investigators Group A European observational study to evaluate the safety and the effectiveness of safinamide in routine clinical practice: The SYNAPSES Trial. J Parkinsons Dis. 2021;11(1):187–198. doi: 10.3233/JPD-219007. - DOI - PMC - PubMed
    1. Bali NR, Salve PS. Impact of rasagiline nanoparticles on brain targeting efficiency via gellan gum based transdermal patch: a nanotheranostic perspective for Parkinsonism. Int J Biol Macromol. 2020;164:1006–1024. doi: 10.1016/j.ijbiomac.2020.06.261. - DOI - PubMed
    1. Bar Am O, Amit T, Youdim MBH. Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline. Neurosci Lett. 2004;355:169–172. doi: 10.1016/j.neulet.2003.10.067. - DOI - PubMed
    1. Barone P, Santangelo G, Morgante L, Onofrj M, Meco G, Abbruzzese G, Bonuccelli U, Cossu G, Pezzoli G, Stanzione P, Lopiano L, Antonini A, Tinazzi M. A randomized clinical trial to evaluate the effects of rasagiline on depressive symptoms in non-demented Parkinson’s disease patients. Eur J Neurol. 2015;22(8):1184–1191. doi: 10.1111/ene.12724. - DOI - PMC - PubMed
    1. Barone P, Fernandez HH, Ferreira J et al (2013) Safinamide as an add-on therapy to a stable dose of a single dopamine agonist: results from a randomized, placebo-controlled, 24-week multicenter trial in early idiopathic Parkinson disease (PD) patients (MOTION Study). Neurology 80 (Meeting Abstracts 1): P01.061

MeSH terms